HOME Research Insight Product Launches and Approvals are the Key Growth Strategies Adopted by Market Players in the Infectious Disease Diagnostics Market



Product Launches and Approvals are the Key Growth Strategies Adopted by Market Players in the Infectious Disease Diagnostics Market


The major players operating in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMérieux (France), Bio-Rad (US), and Roche (Switzerland). The global infectious disease diagnostics market is expected to reach USD 19.35 Billion by 2022 from USD 14.73 Billion in 2017, at a CAGR of 5.6%. The increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics are the major factors driving the growth of the infectious disease diagnostics market.

Most companies focus on product launches and approvals to compete in the market. The players also focus on increasing their presence in high-growth markets through acquisitions, agreements, partnerships, collaborations, and expansions. Abbott (US), Becton, Dickinson and Company (BD) (US), biomérieux (France), Bio-Rad (US), and Roche (Switzerland) focus on product launches and approvals to strengthen their positions in the market.

Roche is the leading player in the infectious diagnostics market and offers different test kits and systems. The company mainly focuses on organic strategies like R&D investment and product launches & approvals. The company has R&D sites in 22 locations. In 2016, the company invested ~13% of its total revenue in R&D to come up with new product offerings. The company also focuses on collaborations, for instance, Roche entered into a strategic partnership with GE Healthcare to develop digital clinical decision solutions.

Abbott is one of the leading players in the global infectious disease diagnostics market. The company offers a wide range of products including assays & reagents and informatics solutions & services. Abbott focuses on strengthening its position in the market by adopting organic and inorganic strategies such as product launches, acquisitions, collaborations, and expansions. With its strong geographic presence and extensive product portfolio, the company is expected to witness significant growth in the infectious disease diagnostics market during the forecast period.

Danaher stands among the leading players in the infectious disease diagnostics market. The company offers analytical instruments, reagents, consumables, and software through its subsidiaries Beckman Coulter and Cepheid. In November 2016, Danaher acquired Cepheid (US) to expand its diagnostics business with Cepheid’s molecular diagnostic systems and tests. The company’s broad product portfolio and focus on improving its R&D capabilities to introduce new products into the market is expected to help the company maintain and enhance its position in the market.

Related Reports:

Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports